Skip to main content
Valbiotis logo

Valbiotis — Investor Relations & Filings

Ticker · ALVAL ISIN · FR0013254851 LEI · 969500VP4JBJCF0MOP60 PA Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country FR France
Listing PA ALVAL

About Valbiotis

https://www.valbiotis.com/en/

Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.

Recent filings

Filing Released Lang Actions
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 30% confidence The document is a corporate press release announcing the creation of a new subsidiary in Singapore via a joint venture, outlining business expansion and commercial launch plans. It contains no financial statements, no regulatory certification of a report, no share issuance or repurchase details, no dividend notice, no earnings figures, and no governance or M&A bid. It is a general business update and thus falls under the fallback category for miscellaneous regulatory announcements.
2026-05-11 English
VALBIOTIS SA: Valbiotis poursuit son déploiement en Asie
Regulatory Filings Classification · 75% confidence The document is a press release (“communiqué de presse”) announcing the creation of a new subsidiary in Singapore by a Chinese joint venture and outlining the company’s business expansion in Asia. It contains no financial results, no specific report attachments, no regulatory certifications, no share transactions, and no invitation to vote or vote results. It is not an investor presentation, earnings release, management report, or interim/annual report. Therefore, it fits best into the fallback category for general corporate/regulatory announcements. Classification: Regulatory Filings (RNS).
2026-05-11 French
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Regulatory Filings Classification · 90% confidence The document is a French Regulatory News press release (inside information) announcing the business expansion of Valbiotis in Asia. It contains no financial statements, management changes, capital transactions, or results. It is a general corporate announcement distributed via a regulatory news service. It therefore falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-11 English
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2026-05-07 French
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Regulatory Filings
2026-05-07 French
VALBIOTIS SA: Valbiotis expands its e-commerce to Belgium and Luxembourg
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing the expansion of Valbiotis’ e-commerce delivery to Belgium and Luxembourg. It does not contain financial results, regulatory filings, board changes, dividends, or other report types. It is a general announcement that does not fit any specific category, so it defaults to a Regulatory Filings (RNS) fallback.
2026-04-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.